The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Abstract
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours 1,2. We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma-in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733). We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma. Clinical responses are accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens. The antigen-specific cytotoxic T-cell responses in some responders reach magnitudes typically reported for adoptive T-cell therapy, and are durable. Our findings indicate that RNA-LPX vaccination is a potent immunotherapy in patients with CPI-experienced melanoma, and suggest the general utility of non-mutant shared tumour antigens as targets for cancer vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [18]
In the citing paper
“Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.345,350–352”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [345]
In the citing paper
“For example, FixVac, which was developed based on the RNA-LPX formulation, is a systemic mRNA vaccine encoding four non-mutated antigens of melanoma200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“After the eighth immunization, more than 75% of patients generated immune responses against at least one tumour-associated antigen, and CD8+ T cells played a major role in high-magnitude T cell responses200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“Moreover, a combination of FixVac/anti-programmed cell death protein 1 (PD1) antibody augmented the antitumour effect of FixVac, resulting in a >35% tumour regression rate in immune checkpoint inhibitor-experienced patients200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“The interim analysis from the phase I trial (NCT02410733) showed that the metabolic activity of the spleen increased post the sixth immunization, indicating targeted delivery of FixVac and activation of resident immune cells200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationMiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavskii, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,730
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Cited by
Sorted by citations
Items 201–300 of 1,000
Strategies to overcome DC dysregulation in the tumor microenvironment
Mestrallet, G., Sone, K., & Bhardwaj, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980709 · Cited by 56
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
Yu, M., Yang, W., Yue, W., & Chen, Y. (2022) · Advanced Science · doi:10.1002/advs.202204335 · Cited by 54
Sych, T., Schlegel, J. A., Barriga, H. M. G., Ojansivu, M., Hanke, L., Weber, F., Bostancıoğlu, R. B., Ezzat, K., Stangl, H., Plochberger, B., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01825-5 · Cited by 54
An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer
Yang, L., Chen, X., Wang, K., Li, L., & Zhang, H. (2024) · Vaccines · doi:10.3390/vaccines12070727 · Cited by 55
Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update
Magoola, M., & Niazi, S. K. (2025) · Cancers · doi:10.3390/cancers17111882 · Cited by 58
Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance
Muraoka, D., Harada, N., Shiku, H., & Akiyoshi, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.004 · Cited by 54
He, Y., Zhang, W., Xiao, Q., Fan, L., Huang, D., Chen, W., & He, W. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.11.002 · Cited by 60
Xu, L., Cao, Y., Ya, X., Li, R., & Xu, X. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300238 · Cited by 54
Lipid nanoparticles for RNA delivery: Self-assembling vs driven-assembling strategies
Nele, V., Campani, V., Moosavian, S. A., & Rosa, G. D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115291 · Cited by 58
mRNA vaccines in the context of cancer treatment: from concept to application
Fu, Q., Zhao, X., Hu, J., Jiao, Y., Yan, Y., Pan, X., Wang, X., & Jiao, F. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06033-6 · Cited by 59
Personalized cancer vaccination in head and neck cancer
Shibata, H., Zhou, L., Xu, N., Egloff, A. M., & Uppaluri, R. (2020) · Cancer Science · doi:10.1111/cas.14784 · Cited by 54
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 54
Next-generation cancer vaccines and emerging immunotherapy combinations
Brandenburg, A., Heine, A., & Brossart, P. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.003 · Cited by 52
Maine, C. J., Miyake-Stoner, S. J., Spasova, D. S., Picarda, G. G. A., Chou, A. C., Brand, E. D., Olesiuk, M. D., Domingo, C. C., Little, H. J., Goodman, T. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55843-9 · Cited by 55
Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment
Deng, B., Ma, B., Ma, Y., Cao, P., Leng, X., Huang, P., Zhao, Y., Ji, T., Lu, X., & Liu, L. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01353-5 · Cited by 51
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy
Wilhelmy, C., Keil, I. S., Uebbing, L., Schroer, M. A., Franke, D., Nawroth, T., Barz, M., Şahin, U., Haas, H., Diken, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082068 · Cited by 51
Self-citationNanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
Dang, B.-T. N., Kwon, T. K., Lee, S., Jeong, J., & Yook, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.007 · Cited by 51
Cancer vaccines as enablers of immunotherapy
Khleif, S. N., & Gupta, S. (2025) · Nature Immunology · doi:10.1038/s41590-025-02308-2 · Cited by 56
Patel, A. J., Tan, T.-M., Richter, A. G., Naidu, B. V., Blackburn, J. M., & Middleton, G. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01572-x · Cited by 52
Zhou, Q., Yan, X., Zhu, H., Xin, Z., Zhao, J., Shen, W., Yin, W., Guo, Y., Xu, H., Zhao, M. F., et al. (2021) · Theranostics · doi:10.7150/thno.61677 · Cited by 50
Feng, W., Shi, W., Cui, Y., Xu, J., Liu, S., Gao, H., Zhu, S., Liu, Y., & Zhang, H. (2023) · Theranostics · doi:10.7150/thno.81650 · Cited by 50
Advances in the design and delivery of RNA vaccines for infectious diseases
Lokras, A. G., Bobak, T. R., Baghel, S. S., Sebastiani, F., & Foged, C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115419 · Cited by 52
Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy
Li, H., Hu, Y., Li, J., He, J., Yu, G., Wang, J., & Lin, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02191-1 · Cited by 56
Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC
Şahin, U., Schmidt, M., Derhovanessian, E., Cortini, A., Vogler, I., Omokoko, T., Godehardt, E., Attig, S., Newrzela, S., GRUTZNER, J., et al. (2026) · Nature · doi:10.1038/s41586-025-10004-2 · Cited by 50
Self-citationCellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53
Racacho, K. J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621812 · Cited by 55
Salomon, N., Vascotto, F., Selmi, A., Vormehr, M., Quinkhardt, J., Bukur, T., Schrörs, B., Löewer, M., Diken, M., Türeci, Ö., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771925 · Cited by 49
Self-citationCharting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Vaccines for immunoprevention of DNA mismatch repair deficient cancers
Hernandez‐Sanchez, A., Grossman, M., Yeung, K., Sei, S., Lipkin, S. M., & Kloor, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004416 · Cited by 51
Advances and applications of RNA vaccines in tumor treatment
Yang, R., & Cui, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02141-5 · Cited by 48
Sex hormones, the anticancer immune response, and therapeutic opportunities
Conforti, F., Pala, L., Mitri, D. D., Catania, C., Cocorocchio, E., Laszlo, D., Ceresoli, G. L., Locatelli, M., Facella, F., Pas, T. M. D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.013 · Cited by 48
Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance
Nagy, N. A., de Haas, A. M., Geijtenbeek, T. B. H., van Ree, R., Tas, S. W., van Kooyk, Y., & de Jong, E. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674048 · Cited by 49
Manganese oxide nanomaterials boost cancer immunotherapy
Ding, B., Yue, J., Zheng, P., Ma, P., & Lin, J. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01001h · Cited by 48
Dahlgren, M. W., Plumb, A. W., Niss, K., Lahl, K., Brunak, S., & Johansson‐Lindbom, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932388 · Cited by 48
Yang, P., Meng, M., & Zhou, Q. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188558 · Cited by 51
Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
Zhou, H., Ma, Y., Liu, F., Li, B., Qiao, D., Ren, P., & Wang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1255799 · Cited by 46
Chen, Z., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14500 · Cited by 46
Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges
Bandara, S., & Raveendran, S. (2025) · Cancers · doi:10.3390/cancers17050821 · Cited by 56
A battery-free nanofluidic intracellular delivery patch for internal organs
Yin, D., Wang, P., Hao, Y., Yue, W. W., Jiang, X., Yao, K., Wang, Y., Hang, X., Xiao, A., Zhou, J., et al. (2025) · Nature · doi:10.1038/s41586-025-08943-x · Cited by 48
Yang, K., Hua, B., Qi, S., Bai, B., Yu, C., Huang, F., & Yu, G. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202213572 · Cited by 45
Research progress on the quality control of mRNA vaccines
Hu, C., Bai, Y., Liu, J., Wang, Y., He, Q., Zhang, X., Cheng, F., Xu, M., Mao, Q., & Liang, Z. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2354251 · Cited by 45
Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology
Jacob, E. M., Huang, J., & Chen, M. (2024) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbae017 · Cited by 48
Apavaloaei, A., Zhao, Q., Hesnard, L., Cahuzac, M., Durette, C., Larouche, J., Hardy, M., Vincent, K., Brochu, S., Laverdure, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00979-2 · Cited by 47
Nanotechnology for immuno-oncology
Grippin, A., Lee, D., Parkes, E. E., Jiang, W., & Kim, B. Y. S. (2025) · Nature Cancer · doi:10.1038/s43018-025-01025-x · Cited by 48
Development of Thermally Stable mRNA-LNP Delivery Systems: Current Progress and Future Prospects
Kafle, U., Truong, H. Q., Cao, T. G. N., & Meng, F. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00826 · Cited by 47
Advances in nucleic acid-based cancer vaccines
Liao, H., & Liu, S. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01102-w · Cited by 46
Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives
Chen, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.016 · Cited by 43
Spleen‐targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma
Wu, M., Luo, Z., Cai, Z., Mao, Q., Li, Z., Li, H., Zhang, C., Zhang, Y., Zhong, A., Wu, L., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216836 · Cited by 46
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Therapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 44
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 43
Hewel, C., Wierczeiko, A., Miedema, J., Friedrich, J. H., Hofmann, F., Weißbach, S., Dietrich, V., Holthöfer, L., Haug, V., Mündnich, S., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1314 · Cited by 47
DeMaria, P. J., Lee-Wisdom, K., Donahue, R. N., Madan, R. A., Karzai, F. H., Schwab, A., Palena, C., Jochéms, C., Floudas, C. S., Strauss, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003238 · Cited by 43
Ellingsen, E. B., Aamdal, E., Guren, T. K., Lilleby, W. A., Brunsvig, P. F., Mangsbo, S. M., Aamdal, S., Hovig, E. J., Mensali, N., Gaudernack, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004345 · Cited by 43
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 45
Zhou, P., Liu, W., Cheng, Y., & Qian, D. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1718 · Cited by 42
CD4 T cell–activating neoantigens enhance personalized cancer vaccine efficacy
Huff, A. L., Longway, G., Mitchell, J. T., Andaloori, L., Davis-Marcisak, E. F., Chen, F., Lyman, M. R., Wang, R., Mathew, J., Barrett, B., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.174027 · Cited by 42
Li, Z., Amaya, L., Ee, A., Wang, S. K., Ranjan, A., Waymouth, R. M., Chang, H. Y., & Wender, P. A. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c02704 · Cited by 41
Dong, L., Deng, X., Li, Y., Zhu, X., Shu, M., Chen, J., Luo, H., An, K., Cheng, M., Zhang, P., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c04331 · Cited by 42
Wells, K., Liu, T., Zhu, L., & Yang, L. P. H. (2024) · Nanoscale · doi:10.1039/d4nr01780c · Cited by 42
An mRNA vaccine elicits STING-dependent antitumor immune responses
Chen, Z., Meng, C., Mai, J., Liu, Y., Li, H., & Shen, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.013 · Cited by 41
Cancer immunotherapies: A hope for the uncurable?
Hamdan, F., & Cerullo, V. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140977 · Cited by 41
Deyhimfar, R., Izady, M., Shoghi, M., Kazazi, M. H., Ghazvini, Z. F., Nazari, H., Fekrirad, Z., & Arefian, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26971 · Cited by 42
Venzin, V., Beccaría, C. G., Perucchini, C., Delfino, P., Bono, E. B., Giustini, L., Moalli, F., Grillo, M., Fumagalli, V., Laura, C., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02199-3 · Cited by 41
Self-citationYan, J., Zhang, H., Li, G., Su, J., Wei, Y., & Xu, C. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.10.012 · Cited by 40
Bao, Y., Qiao, Y., Choi, J. E., Zhang, Y., Mannan, R., Cheng, C., He, T., Zheng, Y., Yu, J., Gondal, M. N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314416120 · Cited by 39
mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy
Haghmorad, D., Eslami, M., Orooji, N., Halabitska, I., Kamyshna, I. I., Kamyshnyi, O., & Oksenych, V. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1547025 · Cited by 42
Rational design of lipid nanoparticles for enabling gene therapies
Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 45
Long-acting vaccine delivery systems
Walvekar, P., Kumar, P., & Choonara, Y. E. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114897 · Cited by 39
Cancer vaccines: shared tumor antigens return to the spotlight
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00364-8 · Cited by 39
Clinical and Translational Advances in Glioma Immunotherapy
Bunse, L., Bunse, T., Krämer, C., Chih, Y., & Platten, M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01313-9 · Cited by 40
Nanocarrier vaccine therapeutics for global infectious and chronic diseases
Simnani, F. Z., Singh, D., Patel, P., Choudhury, A., Sinha, A., Nandi, A., Samal, S. K., Verma, S. K., & Panda, P. K. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.008 · Cited by 38
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 39
Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation
Rahmat, J. N., Liu, J., Chen, T., Li, Z., & Zhang, Y. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00602f · Cited by 38
Boosting CAR-T cell therapy through vaccine synergy
Li, Y.-R., Lyu, Z., Shen, X., Fang, Y., & Yang, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.004 · Cited by 40
Dölen, Y., Gileadi, U., Chen, J., Valente, M., Creemers, J. H. A., van Dinther, E. A. W., van Riessen, N. K., Jäger, E., Hrubý, M., Cerundolo, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641703 · Cited by 37
Self-citationWilliamson, L. M., Rive, C. M., Francesco, D. D., Titmuss, E., Chun, H.-J. E., Brown, S. D., Milne, K., Pleasance, E., Lee, A. F., Yip, S. S. F., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00238-4 · Cited by 38
Zhang, H., Bussmann, J., Huhnke, F. H., Devoldere, J., Minnaert, A., Jiskoot, W., Serwane, F., Spatz, J. P., Röding, M., Smedt, S. C. D., et al. (2021) · Advanced Science · doi:10.1002/advs.202102072 · Cited by 37
Shining Light on Polymeric Drug Nanocarriers with Fluorescence Correlation Spectroscopy
Schmitt, S., Nuhn, L., Barz, M., Butt, H., & Koynov, K. (2022) · Macromolecular Rapid Communications · doi:10.1002/marc.202100892 · Cited by 38
Stereocontrolled access to thioisosteres of nucleoside di- and triphosphates
Zhang, H., Ociepa, M., Nassir, M., Zheng, B., Lewicki, S. A., Salmaso, V., Baburi, H., Nagel, J., Mirza, S., Bueschbell, B., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01347-2 · Cited by 36
Advances and prospects of precision nanomedicine in personalized tumor theranostics
Mao, Y., Xie, J., Yang, F., Luo, Y., Du, J., & Xiang, H. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1514399 · Cited by 38
Mehta, A., Motavaf, M., Nebo, I. D., Luyten, S., Osei-Opare, K. D., & Gru, A. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041200 · Cited by 38
DNA Nanodevices with Selective Immune Cell Interaction and Function
Arulkumaran, N., Lanphere, C., Gaupp, C., Burns, J. R., Singer, M., & Howorka, S. (2021) · ACS Nano · doi:10.1021/acsnano.0c07915 · Cited by 37
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
Elkrief, A., Wu, J. T.-Y., Jani, C., Enriquez, K. T., Glover, M. J., Shah, M. R., Shaikh, H. G., Beeghly-Fadiel, A. C., French, B. C., Jhawar, S. R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1368 · Cited by 36
Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39
Wang, S., Chen, L., & Liu, W. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02634-7 · Cited by 36
Shi, Y., Huang, J., Liu, Y., Liu, J., Guo, X., Li, J., Gong, L., Zhou, X., Cheng, G., Qiu, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo1827 · Cited by 36
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
Yang, W., Cao, J., Cheng, H., Chen, L., Yu, M., Chen, Y., & Cui, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.014 · Cited by 36
The application of nanoparticles in immunotherapy for hepatocellular carcinoma
Hu, X., Zhu, H., He, X., Chen, J., Xiong, L., Shen, Y., Li, J., Xu, Y., Chen, W., Liu, X., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.051 · Cited by 35
Ninmer, E. K., Zhu, H., Chianese‐Bullock, K. A., von Mehren, M., Haas, N. B., Ross, M. I., Dengel, L. T., & Slingluff, C. L. (2024) · Nature Communications · doi:10.1038/s41467-024-46877-6 · Cited by 35
Jacobson, M. E., Becker, K. W., Palmer, C. R., Pastora, L. E., Fletcher, R. B., Collins, K. A., Fedorova, O., Duvall, C. L., Pyle, A. M., & Wilson, J. T. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00568 · Cited by 35
Fobian, S., Cheng, Z., & ten Hagen, T. L. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010026 · Cited by 35
Wang, K., Wang, X., Jiang, D. M., Pei, Y., Wang, Z., Zhou, X., Wu, J., Mo, X., & Wang, H. (2022) · Composites Part B Engineering · doi:10.1016/j.compositesb.2022.109648 · Cited by 35
Nanodrugs Targeting T Cells in Tumor Therapy
Haist, M., Mailänder, V., & Bros, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912594 · Cited by 36
Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines
Bolhassani, A. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00624-8 · Cited by 36
Cassaniti, I., Bergami, F., Percivalle, E., Gabanti, E., Sammartino, J. C., Ferrari, A., Adzasehoun, K. M. G., Zavaglio, F., Zelini, P., Comolli, G., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.016 · Cited by 36
Emerging advances in delivery systems for mRNA cancer vaccines
Jiang, Z., Xu, Y., Du, G., & Sun, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.039 · Cited by 35
Laila, U. E., An, W., & Xu, Z.-X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448489 · Cited by 34
Metadata
- Authors
- Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., Tolliver, C., Caspar, J., Quinkhardt, J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M., Müller, V., Mitzel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann, R., Hassel, J. C., Loquai, C., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- University Hospital Frankfurt (DE)
- ORCID
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 585
- Issue
- 7823
- Pages
- 107-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3046115489
- Cited by
- 1,052
- References
- 36
- Citations by year
- 2026: 140 · 2025: 204 · 2024: 191 · 2023: 190 · 2022: 174 · 2021: 131 · 2020: 21
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- RNA vaccines, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, tumor-associated antigens, cancer immunotherapy, CD4+ T cells, CD8+ T cells, cytotoxic T lymphocyte response
- MeSH terms
- Antigens, Neoplasm, Antineoplastic Agents, Combined Modality Therapy, Humans, Melanoma, Neoplasm Staging, RNA, Neoplasm, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Vaccination, Cancer Vaccines, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
